| Menopause References |
|
1. CDC, Centers for Disease Control and Prevention, "Women's Reproductive Health: Menopause. Available at: http://www.cdc.gov/reproductivehealth//WomensRH/Menopause.htm
2. Pizzorno JE and Murray MT, eds. Encyclopedia of Natural Medicine, revised 2nd edition, CA: Prima Publishing, 1998: 628-644.
3. Stoppard M. Family Health Guide, New York: DK Publishing, 2002: 497-503.
4.
Writing Group for the Women's
Health Initiative Investigators.
Women's Health Initiative. Risks
and benefits of estrogen plus
progestin in healthy
postmenopausal women: principal
results from the Women's Health
Initiative randomized controlled
trial. JAMA.
Jul2002;288(3):321-33. 5. Hulley S et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study follow-up (HERS). JAMA. 1998;280:605-613
6. Grady D et al, HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. Jul2002;288(1):49-57.
7. Schairer et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. Jul2000;283: 485-491.
8. Lee CJ et al. Effects of supplementation of the diets with calcium and calcium-rich foods on bone density of elderly females with osteoporosis. Am J Clin Nutr 1981; (34):819-823.
9. Reid IR et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. Am J J Med 1995;(08):331-335
10. Wishart JM, Clifton PM, Nordin BE. Effect of perimenopause on calcium absorption: a longitudinal study. Climacteric. Jun2000;3(2):102-8.
11. Murray MT. Encyclopedia of Nutritional Supplements, NY: Three Rivers Press, 1996: 156.
12.
Cohen L et al. Infrared
spectroscopy and magnesium content
of bone mneral in osteoporotic
women. Isr J Med Sci
1981;(17):1123-1125
13.
Sojka JE, et al. Magnesium
Supplementation and Osteoporosis.
Nutr Rev. 1995;53(3):71-74.
14.
Tranquilli AL, et al. Calcium,
Phosphorus, and Magnesium Intakes
Correlate with Bone Mineral
Content in Postmenopausal Women.
Gynecol Endrocrinol.
1994;8(1):55-58.
15.
Altura BM, et al. Role of
Magnesium in Patho-physiological
Processes and the Clinical Utility
of Magnesium Ion Selective
Electrodes. Scand J Clin Lab
Invest. 1996;224S: 211-34.
17.
Villareal DT, et al. Subclinical
Vitamin D Deficiency in
Postmenopausal Women with Low
Vertebral Bone Mass. Journal of
Clinical Endocrinology and
Metabolism. 1991;72(3):628-34.
18.
Rassouli A, Milanian I,
Moslemi-Zadeh M. Determination of
serum 25-hydroxyvitamin D(3)
levels in early postmenopausal
Iranian women: relationship with
bone mineral density. Bone.
Nov2001;29(5):428-30.
19.
Mezquita-Raya P, Munoz-Torres M,
Luna JD, et al. Relation between
vitamin D insufficiency, bone
density, and bone metabolism in
healthy postmenopausal women. J
Bone Miner Res.
Aug2001;16(8):1408-15.
20.
Brot C, Vestergaard P, Kolthoff N,
Gram J, Hermann AP, Sorensen OH.
Vitamin D status and its adequacy
in healthy Danish perimenopausal
women: relationships to dietary
intake, sun exposure and serum
parathyroid hormone. Br J Nutr.
Aug2001;86(Suppl 1):S97-103.
21.
Mezquita Raya P, Munoz Torres M,
Lopez Rodriguez F, et al.
Prevalence of vitamin D deficiency
in populations at risk for
osteoporosis: impact on bone
integrity. Med Clin (Barc).
Jun2002;119(3):85-9. 22. Pizzorno JE and Murray MT, eds. Encyclopedia of Natural Medicine, revised 2nd edition, CA: Prima Publishing, 1998: 638.
23.
Morton DJ, Barrett-Connor EL,
Schneider DL. Vitamin C supplement
use and bone mineral density in
postmenopausal women. J Bone Miner
Res. Jan2001;16(1):135-40.
24.
Hall SL, Greendale GA. The
relation of dietary vitamin C
intake to bone mineral density:
results from the PEPI study.
Calcif Tissue Int.
Sep1998;63(3):183-9.
25.
Wang MC, Luz Villa M, Marcus R,
Kelsey JL. Associations of vitamin
C, calcium and protein with bone
mass in postmenopausal Mexican
American women. Osteoporos Int.
1997;7(6):533-8.
26.
Leveille SG, LaCroix AZ, Koepsell
TD, Beresford SA, Van Belle G,
Buchner DM. Dietary vitamin C and
bone mineral density in
postmenopausal women in Washington
State, USA. J Epidemiol Community
Health. Oct1997;51(5):479-85.
27.
Kritz-Silverstein D, Goodman-Gruen
DL. Usual dietary isoflavone
intake, bone mineral density, and
bone metabolism in postmenopausal
women. J Womens Health Gend Based
Med. Jan2002;11(1):69-78.
28.
Adlercreutz H. Soybean
phytoestrogen intake and cancer
risk.
29.
Cotroneo MS, Wang J, Fritz WA,
Eltoum IE, Lamartiniere CA.
Genistein action in the
prepubertal mammary gland in a
chemoprevention model.
Carcinogenesis.
Sep2002;23(9):1467-1474.
30.
Wu AH, Wan P, Hankin J, Tseng CC,
Yu MC, Pike MC. Adolescent and
adult soy intake and risk of
breast cancer in Asian-Americans.
Carcinogenesis.
Sep2002;23(9):1491-6.
31.
Ishimi Y, et al. Selective effects
of genistein, a soybean
isoflavone, on B-lymphopoiesis and
bone loss caused by estrogen
deficiency. Endocrinology.
1999;140:1893-1900.
32.
Setchell KD, et al. Dietary
isoflavones: biological effects
and relevance to human health. J
Nutr. 1999;129:758S-767S.
33.
Allred CD, Allred KF, Ju YH, et
al. Soy diets containing varying
amounts of genistein stimulate
growth of estrogen-dependent
(MCF-7) tumors in a dose-dependent
manner. Cancer Res.
Jul2001;61(13):5045-50.
34.
Hsieh CY, Santell RC, Haslam SZ,
Helferich WG. Estrogenic effects
of genistein on the growth of
estrogen receptor-positive human
breast cancer (MCF-7) cells in
vitro and in vivo. Cancer Res.
Sep1998;58(17):3833-8.
35.
Ju YH, Doerge DR, Allred KF,
Allred CD, Helferich WG. Dietary
Genistein Negates the Inhibitory
Effect of Tamoxifen on Growth of
Estrogen-dependent Human Breast
Cancer (MCF-7) Cells Implanted in
Athymic Mice. Cancer Res.
May2002;62(9):2474-7. 36. Ishihara M. Effect of of gamma-oryzanol on serum lipid peroxide levels and climacteric disturbances. Asia Oceania J Ostet Gynecol 1984; 10:317
37.
Ishihara M, Ito Y, Nakakita T, et
al. Clinical effect of gamma-oryzanol
on climacteric disturbance -on
serum lipid peroxides. Nippon
Sanka Fujinka Gakkai Zasshi.
Feb1982;34(2):243-51.
38.
Lucas EA, Wild RD, Hammond LJ,
Khalil DA, Juma S, Daggy BP, et
al. Flaxseed improves lipid
profile without altering
biomarkers of bone metabolism in
postmenopausal women. J Clin
Endocrinol Metab.
Apr2002;87(4):1527-32.
39.
Hutchins AM, Martini MC, Olson BA,
Thomas W, Slavin JL. Flaxseed
consumption influences endogenous
hormone concentrations in
postmenopausal women. Nutr Cancer.
2001;39(1):58-65. 40. Pizzorno JE and Murray MT, eds. Encyclopedia of Natural Medicine, revised 2nd edition, CA: Prima Publishing, 1998: 639.
41.
Hirata JD, Swiersz LM, Zell B,
Small R, Ettinger B. Does dong
quai have estrogenic effects in
postmenopausal women? A
double-blind, placebo-controlled
trial. Fertil Steril.
Dec1997;68(6):981-6.
42.
Willhite LA, O'Connell MB.
Urogenital atrophy: prevention and
treatment. Pharmacotherapy.
Apr2001;21(4):464-80.
43.
Hardy ML. Herbs of special
interest to women. J Am Pharm
Assoc (Wash).
Mar2000;40(2):234-42.
44.
Shaw CR. The perimenopausal hot
flash: epidemiology, physiology,
and treatment. Nurse Pract.
Mar1997;22(3):55-6, 61-6.
45.
Lieberman S. A Review of the
Effectiveness of Cimicifuga
racemosa (black cohosh) for the
Symptoms of Menopause. J Womens
Health. Jun1998;7(5):525-29.
46.
Dog TL, Powell KL, Weisman SM.
Critical evaluation of the safety
of Cimicifuga racemosa in
menopause symptom relief.
Menopause. Jul2003;10(4):299-313.
47.
McKenna DJ, et al. Black cohosh:
efficacy, safety, and use in
clinical and preclinical
applications. Altern Ther Health
Med. May2001;7(3):93-100.
48.
Liske E, et al. Physiological
investigation of a unique extract
of black cohosh (Cimicifugae
racemosae rhizoma): a 6-month
clinical study demonstrates no
systemic estrogenic effect. J
Womens Health Gend Based Med.
Mar2002;11(2):163-74.
49.
Milewicz A, et al. Vitex Agnus
castus Extract in the Treatment of
Luteal Phase Defects Due to Latent
Hyperprolactinemia. Results of a
Randomized Placebo-controlled
Double-blind Study. Arzneim Forsch/Drug
Res. 1993;43(7):752-56.
50.
Bhargava SK. Antiandrogenic
Effects of a Flavonoid-rich
Fraction of Vitex Negundo Seeds: A
Histological and Biochemical Study
in Dogs. J Ethnopharmacol.
1989;27(3):327-39.
51.
Jarry H, et al. In Vitro Prolactin
But Not LH and FSH Release Is
Inhibited by Compounds in Extracts
of Agnus castus: Direct Evidence
for a Dopaminergic Principle by
the Dopamine Receptor Assay. Exp
Clin Endocrinol.
1994;102(6):448-54.
52.
Makwana HG, et al. General
Pharmacology of Vitex leucoxylon
Linn Leaves. Indian J Physiol
Pharmacol. 1994;38(2):95-100.
53.
Liu J, Burdette JE, Xu H, Gu C,
van Breemen RB, Bhat KP, et al.
Evaluation of estrogenic activity
of plant extracts for the
potential treatment of menopausal
symptoms. J Agric Food Chem. May
2001;49(5):2472-9.
54.
Knight DC, Howes JB, Eden JA. The
effect of Promensil, an isoflavone
extract, on menopausal symptoms.
Climacteric. Jun1999;2(2):79-84.
55.
van de Weijer P, Barentsen R.
Isoflavones from red clover (Promensil(R))
significantly reduce menopausal
hot flush symptoms compared with
placebo. Maturitas.
Jul2002;42(3):187.
56.
Morrison MF, et al. DHEA-S levels
and depressive symptoms in a
cohort of African American and
Caucasian women in the late
reproductive years. Biol
Psychiatry. Nov2001;50(9):705-11.
57.
Wolkowitz OM, et al.
Dehydroepiandrosterone (DHEA)
Treatment of Depression. Biol
Psychiatry. Feb1997;41(3):311-18.
58.
Nagata C, et al. Serum
concentrations of estradiol and
dehydroepiandrosterone sulfate and
soy product intake in relation to
psychologic well-being in peri-
and postmenopausal Japanese women.
Metabolism. Dec2000;49(12):1561-4.
59.
Hackbert L, Heiman JR. Acute
dehydroepiandrosterone (DHEA)
effects on sexual arousal in
postmenopausal women. J Womens
Health Gend Based Med.
Mar2002;11(2):155-62.
60.
Takayanagi R, et al.
Dehydroepiandrosterone (DHEA) as a
possible source for estrogen
formation in bone cells:
correlation between bone mineral
density and serum DHEA-sulfate
concentration in postmenopausal
women, and the presence of
aromatase to be enhanced by
1,25-dihydroxyvitamin D3 in human
osteoblasts. Mech Ageing Dev.
Apr2002;123(8):1107-14.
61.
Lasco A, Frisina N, Morabito N, et
al. Metabolic effects of
dehydroepiandrosterone replacement
therapy in postmenopausal women.
Eur J Endocrinol.
Oct2001;145(4):457-61. 62. Genazzani AD, et al. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril. Aug2001;76(2):241-8.
|